당뇨병 관련 안과 치료 시장 규모, 점유율, 동향 분석 보고서 : 용도별, 유형별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

Diabetes Associated Ophthalmic Treatment Market Growth & Trends:

The global diabetes associated ophthalmic treatment market size is expected to reach USD 51.33 billion by 2030, registering to grow at a CAGR of 6.9% from 2024 to 2030 according to a new report by Grand View Research, Inc. The increasing prevalence of type II diabetes, geriatric population, and availability of early detection techniques are some of the factors driving the growth. This is coupled with technological advancements and increasing awareness of early diagnostics to help increase the success rate of the available treatment options. An increasing number of clinical trials to assess new drugs and devices for the prevention and management of these ophthalmic conditions are expected to fuel market growth in upcoming years.

COVID-19 related diabetic and ophthalmic complications are expected to boost the market for diabetes associated ophthalmic treatment methods. COVID-19 has a long-term effect on diabetic conditions. This is expected to increase the demand for treatment procedures in upcoming years. An increasing number of initiatives being undertaken by governments and nonprofit organizations to increase diabetes associated ophthalmic disease awareness is expected to boost the adoption of devices used for the treatment. Furthermore, WHO and IDF are working together to prevent and control diabetes and ensure good quality of life for people worldwide by providing accessible treatment facilities.

Diabetes Associated Ophthalmic Treatment Market Report Highlights:

• The diabetic retinopathy segment has captured the largest revenue share in 2023 followed by diabetic associated macular degeneration and glaucoma
• The drugs segment dominated the market and accounted for the highest revenue share in 2023 owing to factors such as the presence of major key players operating in the global market, high adoption rate, increased clinical trials to develop innovative drugs
• The hospitals segment is predicted to witness the fastest growth rate over the forecast timeframe due to the increasing number of patient visits and advanced infrastructure in hospitals as compared to other healthcare facilities. An increasing number of hospital admissions of diabetes patients is boosting the demand for the segment, thereby propelling the growth
• North America held the largest revenue share in the market and is expected to maintain its dominance over the forecast period

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Information or Data Analysis
  • 1.3.3. Market Formulation & Data Visualization
  • 1.3.4. Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. The Diabetes Associated Ophthalmic Treatment Market Variables, Trends, & Scope

• 3.1. Market Introduction/Lineage Outlook
• 3.2. Market Size and Growth Prospects (USD Million)
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers Analysis
  • 3.3.2. Market Restraints Analysis
• 3.4. The Diabetes Associated Ophthalmic Treatment Market Analysis Tools
  • 3.4.1. Porter's Analysis
    • 3.4.1.1. Bargaining power of the suppliers
    • 3.4.1.2. Bargaining power of the buyers
    • 3.4.1.3. Threats of substitution
    • 3.4.1.4. Threats from new entrants
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Economic and Social landscape
    • 3.4.2.3. Technological landscape
    • 3.4.2.4. Environmental landscape
    • 3.4.2.5. Legal landscape

Chapter 4. Diabetes Associated Ophthalmic Treatment Market: Application Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Diabetes Associated Ophthalmic Treatment Market: Application Movement Analysis, 2023 & 2030 (USD Billion)
• 4.3. Dry Eye Syndrome
  • 4.3.1. Dry Eye Syndrome Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.4. Glaucoma
  • 4.4.1. Glaucoma Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Eye Allergy & Infection
  • 4.5.1. Eye Allergy & Infection Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Diabetic Retinopathy
  • 4.6.1. Diabetic Retinopathy Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.7. Diabetic associated Macular Degeneration
  • 4.7.1. Diabetic associated Macular Degeneration Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.8. Uveitis
  • 4.8.1. Uveitis Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.9. Cataract
  • 4.9.1. Cataract Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.10. Diabetic Macular Edema
  • 4.10.1. Diabetic Macular Edema Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.11. Others
  • 4.11.1. Others Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Diabetes Associated Ophthalmic Treatment Market: Type Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Diabetes Associated Ophthalmic Treatment Market: Type Analysis, 2023 & 2030 (USD Billion)
• 5.3. Drugs
  • 5.3.1. Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.4. Devices
  • 5.4.1. Devices Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Diabetes Associated Ophthalmic Treatment Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Diabetes Associated Ophthalmic Treatment Market: End Use & Trend Analysis, 2023 & 2030 (USD Billion)
• 6.3. Hospitals
  • 6.3.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.4. Ophthalmic Centres
  • 6.4.1. Ophthalmic Centres Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Ambulatory Centres
  • 6.5.1. Ambulatory Centres Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Diabetes Associated Ophthalmic Treatment Market: Regional Estimates & Trend Analysis

• 7.1. Diabetes Associated Ophthalmic Treatment Market Share, By Region, 2023 & 2030 (USD Billion)
• 7.2. Europe
  • 7.2.1. UK Diabetes Associated Ophthalmic Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.2. Germany
    • 7.2.2.1. Germany Diabetes Associated Ophthalmic Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.3. France
    • 7.2.3.1. France Diabetes Associated Ophthalmic Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.4. Italy
    • 7.2.4.1. Italy Diabetes Associated Ophthalmic Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.5. Spain
    • 7.2.5.1. Spain Diabetes Associated Ophthalmic Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.6. Denmark
    • 7.2.6.1. Denmark Diabetes Associated Ophthalmic Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.7. Sweden
    • 7.2.7.1. Sweden Diabetes Associated Ophthalmic Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.8. Norway
    • 7.2.8.1. Norway Diabetes Associated Ophthalmic Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.3. Middle East and Africa
  • 7.3.1. South Africa Diabetes Associated Ophthalmic Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.2. Saudi Arabia
    • 7.3.2.1. Saudi Arabia Diabetes Associated Ophthalmic Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.3. UAE
    • 7.3.3.1. UAE Diabetes Associated Ophthalmic Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.4. Kuwait
    • 7.3.4.1. Kuwait Diabetes Associated Ophthalmic Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis by Key Market Participants
• 8.2. Company Categorization
• 8.3. Company Heat Map Analysis
• 8.4. Company Profiles
  • 8.4.1. Alcon
    • 8.4.1.1. Participant's Overview
    • 8.4.1.2. Financial Performance
    • 8.4.1.3. Product Benchmarking
    • 8.4.1.4. Recent Developments/ Strategic Initiatives
  • 8.4.2. Johnson & Johnson Services, Inc.
    • 8.4.2.1. Participant's Overview
    • 8.4.2.2. Financial Performance
    • 8.4.2.3. Product Benchmarking
    • 8.4.2.4. Recent Developments/ Strategic Initiatives
  • 8.4.3. Bausch Health
    • 8.4.3.1. Participant's Overview
    • 8.4.3.2. Financial Performance
    • 8.4.3.3. Product Benchmarking
    • 8.4.3.4. Recent Developments/ Strategic Initiatives
  • 8.4.4. F. Hoffmann-La Roche Ltd
    • 8.4.4.1. Participant's Overview
    • 8.4.4.2. Financial Performance
    • 8.4.4.3. Product Benchmarking
    • 8.4.4.4. Recent Developments/ Strategic Initiatives
  • 8.4.5. Allergan
    • 8.4.5.1. Participant's Overview
    • 8.4.5.2. Financial Performance
    • 8.4.5.3. Product Benchmarking
    • 8.4.5.4. Recent Developments/ Strategic Initiatives
  • 8.4.6. Bayer AG
    • 8.4.6.1. Participant's Overview
    • 8.4.6.2. Financial Performance
    • 8.4.6.3. Product Benchmarking
    • 8.4.6.4. Recent Developments/ Strategic Initiatives
  • 8.4.7. Santen Pharmaceutical Co. Ltd.
    • 8.4.7.1. Participant's Overview
    • 8.4.7.2. Financial Performance
    • 8.4.7.3. Product Benchmarking
    • 8.4.7.4. Recent Developments/ Strategic Initiatives
  • 8.4.8. Novartis AG
    • 8.4.8.1. Participant's Overview
    • 8.4.8.2. Financial Performance
    • 8.4.8.3. Product Benchmarking
    • 8.4.8.4. Recent Developments/ Strategic Initiatives
  • 8.4.9. Pfizer, Inc.
    • 8.4.9.1. Participant's Overview
    • 8.4.9.2. Financial Performance
    • 8.4.9.3. Product Benchmarking
    • 8.4.9.4. Recent Developments/ Strategic Initiatives
  • 8.4.10. Genentech, Inc.
    • 8.4.10.1. Participant's Overview
    • 8.4.10.2. Financial Performance
    • 8.4.10.3. Product Benchmarking
    • 8.4.10.4. Recent Developments/ Strategic Initiatives
  • 8.4.11. Carl Zeiss Meditec
    • 8.4.11.1. Participant's Overview
    • 8.4.11.2. Financial Performance
    • 8.4.11.3. Product Benchmarking
    • 8.4.11.4. Recent Developments/ Strategic Initiatives
  • 8.4.12. Lumenis
    • 8.4.12.1. Participant's Overview
    • 8.4.12.2. Financial Performance
    • 8.4.12.3. Product Benchmarking
    • 8.4.12.4. Recent Developments/ Strategic Initiatives
  • 8.4.13. Ellex Medical Lasers Ltd.
    • 8.4.13.1. Participant's Overview
    • 8.4.13.2. Financial Performance
    • 8.4.13.3. Product Benchmarking
    • 8.4.13.4. Recent Developments/ Strategic Initiatives
  • 8.4.14. IRIDEX Corp.
    • 8.4.14.1. Participant's Overview
    • 8.4.14.2. Financial Performance
    • 8.4.14.3. Product Benchmarking
    • 8.4.14.4. Recent Developments/ Strategic Initiatives
  • 8.4.15. Topcon Corp.
    • 8.4.15.1. Participant's Overview
    • 8.4.15.2. Financial Performance
    • 8.4.15.3. Product Benchmarking
    • 8.4.15.4. Recent Developments/ Strategic Initiatives
  • 8.4.16. Abbott Medical Optics
    • 8.4.16.1. Participant's Overview
    • 8.4.16.2. Financial Performance
    • 8.4.16.3. Product Benchmarking
    • 8.4.16.4. Recent Developments/ Strategic Initiatives
  • 8.4.17. Quantel
    • 8.4.17.1. Participant's Overview
    • 8.4.17.2. Financial Performance
    • 8.4.17.3. Product Benchmarking
    • 8.4.17.4. Recent Developments/ Strategic Initiatives